Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 1999

View Archived Issues

Chinese authorities approve Matritech's bladder cancer test

Patient enrollment in Vion's Promycin trial increases during Q2 1999

Emisphere Technologies foresees initiation of phase III testing for oral heparin

Incara subsidiary licenses rights to liver progenitor cell technology

5-HT4 receptor ligands studied extensively at Roche Bioscience

Evacet/Taxol combination enters advanced breast cancer trials

Long-term tolterodine reduces incontinence, is well tolerated

Herceptin approved in Canada for breast cancer therapy

Innogenetics acquires TRAx product line from Avant Immunotherapeutics

Long-term continuation rate good for Alza's overactive bladder therapy

Cerebrus researches GABA-A ligands for treating CNS disorders

AMD-3329 is a more potent derivative of the CXCR4 antagonist AMD-3100

Molecular Biosystems successfully completes phase II studies of Optison

NuOncology Labs awarded second U.S. patent

NaPro BioTherapeutics focuses on new anticancer programs

Tularik discovers new PPAR-gamma modulators for treating diabetes

Cytotoxic macrolide compounds HA-1 and TH-2 obtained from marine sources

Oral bioavailability of thrombin inhibitor S-31922 shows reduced variability in the presence of food

Servier researchers present S-31214, a potent and selective thrombin inhibitor, at ACS

LeukoSite, Kyowa Hakko collaborate on the study of chemokine receptor antagonists

Still in the news: vasopeptidase inhibitor omapatrilat a protagonist in Barcelona

Preclinical studies of abetafen show potential for treatment of prostate disease

News from ACS: hepatitis C viral protease inhibitor BILN-303-SE

LB-42908 inhibits protein farnesyltransferase in vitro, in vivo

Final results of REACH-1 now in, support efficacy of bosentan in CHF

U of M research team studies new compounds for imaging prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...